135046-48-9

(±) Clopidogrel hydrogen sulfate (Iscover) , an antiplatelet agent pharmacologically and structurally analogous to ticlopidine, is used to inhibit blood clots in various conditions such as cerebrovascular disease, peripheral vascular disease, and coronary artery disease.

rac-Clopidogrel-D4 Hydrogen Sulfate is a deuterated compound of Clopidogrel Hydrogen Sulfate (T0182L2). rac-Clopidogrel Hydrogen Sulfate has a CAS number of 135046-48-9. Clopidogrel, an antiplatelet agent pharmacologically and structurally analogous to ticlopidine, is used to inhibit blood clots in various conditions such as cerebrovascular disease, peripheral vascular disease, and coronary artery disease.

Clopidogrel (Standard) is a reference standard for research and analysis in studies involving Clopidogrel. Clopidogrel (SR-25990C), a P2Y12 receptor antagonist, decreases platelet aggregation.

Clopidogrel-D3 hydrogen sulfate is the deuterated form of Clopidogrel hydrogen sulfate. This compound is an anti-platelet agent that prevents thrombus formation by inhibiting platelet aggregation induced by ADP. Clopidogrel hydrogen sulfate effectively inhibits CYP2B6 and CYP2C19 with IC₅₀ values of 18.2 nM and 524 nM, respectively, and it is also an orally active P2Y (12) inhibitor.

Clopidogrel HCl is the salt form of Clopidogrel (free base), an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex.

Clopidogrel is an antithrombic compound whose active metabolite is a selective, irreversible antagonist of the platelet purinergic P2Y12 receptor (IC50 = 100 nM). Clopidogrel inhibits ADP-induced platelet aggregation ex vivo and functions as a prodrug whereupon biotransformation to its active metabolite via CYP2C19 in the liver enables its anti-aggregating activity. Marketed under the name Plavix , clopidogrel in combination with aspirin has been shown to be beneficial in the prevention of vascular ischemic events for patients without deficiencies in CYP2C19-related metabolism.

Clopidogrel hydrogen sulfate ((S)-(+)-Clopidogrel bisulfate) , a selective, high-affinity P2Y12 receptor antagonist, suppressess fibrinogen binding to platelets and platelet adhesion and aggregation.

Clopidogrel-[13C6] Hydrogensulfate (Standard) is a reference standard of Clopidogrel-[13C6] Hydrogensulfate intended for quantitative analysis, quality control, and related biochemical research applications.

Clopidogrel (SR-25990C), a P2Y12 receptor antagonist, decreases platelet aggregation.